Pharmaceutical product liability in the United States of America
Pharmaceuticals Policy and Law · 2018-12 · 20 (1-4) · 23-39
DOI: 10.3233/ppl-180473 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals Policy and Law, 2018-12. Verfasst von Christopher J. Robinette und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Pharmaceutical claims are arguably the most significant type of product liability cases in the United States. Failure to warn is the primary theory used against pharmaceutical manufacturers, and it can be brought under strict product liability or negligence; the standard is essentially the same under either doctrine. In this descriptive overview of United States law, the authors discuss theories of recovery, causation, damages, defences, procedure, and alternative regulations and remedies.
Zitieren
APA
Robinette, C. J., & Green, M. D. (2018). Pharmaceutical product liability in the United States of America. Pharmaceuticals Policy and Law, 20(1-4), 23-39. https://doi.org/10.3233/ppl-180473
Vancouver
Robinette CJ, Green MD. Pharmaceutical product liability in the United States of America. Pharmaceuticals Policy and Law. 2018;20(1-4):23-39. doi:10.3233/ppl-180473
BibTeX
@article{Robinette2018,
author = {Robinette, Christopher J. and Green, Michael D.},
title = {Pharmaceutical product liability in the United States of America},
journal = {Pharmaceuticals Policy and Law},
year = {2018},
volume = {20},
number = {1-4},
pages = {23--39},
doi = {10.3233/ppl-180473}
}
EUVIMED